Corium International, Inc. to Post FY2022 Earnings of $0.86 Per Share, Jefferies Group Forecasts (CORI)

Corium International, Inc. (NASDAQ:CORI) – Investment analysts at Jefferies Group issued their FY2022 earnings per share estimates for shares of Corium International in a report released on Friday. Jefferies Group analyst D. Steinberg forecasts that the biopharmaceutical company will post earnings of $0.86 per share for the year. Jefferies Group currently has a “Buy” rating and a $10.00 price target on the stock.

WARNING: “Corium International, Inc. to Post FY2022 Earnings of $0.86 Per Share, Jefferies Group Forecasts (CORI)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/11/22/corium-international-inc-to-post-fy2022-earnings-of-0-86-per-share-jefferies-group-forecasts-cori.html.

A number of other equities analysts have also recently commented on CORI. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Needham & Company LLC lifted their price target on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright set a $15.00 price target on Corium International and gave the stock a “buy” rating in a report on Friday, November 17th. BidaskClub cut Corium International from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Corium International from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $13.38.

Corium International (NASDAQ:CORI) traded down $0.05 during trading on Monday, reaching $11.29. The company had a trading volume of 120,784 shares, compared to its average volume of 183,276. Corium International has a fifty-two week low of $2.67 and a fifty-two week high of $12.18. The company has a debt-to-equity ratio of 1.89, a current ratio of 7.04 and a quick ratio of 6.80.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of Corium International by 118.1% in the first quarter. Bank of New York Mellon Corp now owns 25,269 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 13,683 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Corium International during the second quarter valued at approximately $158,000. California State Teachers Retirement System acquired a new position in Corium International during the second quarter valued at approximately $263,000. Teachers Advisors LLC acquired a new position in Corium International during the second quarter valued at approximately $272,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Corium International during the second quarter valued at approximately $411,000. Institutional investors own 89.96% of the company’s stock.

In other news, major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of Corium International stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total value of $1,657,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 868,100 shares of company stock valued at $9,538,781. Corporate insiders own 45.70% of the company’s stock.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply